Company intelligence / Profile preview
Damora Therapeutics
- Ownership
- Public · DMRA
- Development stage
- Other
01
Overview
Damora Therapeutics developed anti-mutant calreticulin (mutCALR) targeted therapeutics for myeloproliferative neoplasms. The lead program, DMR-001, demonstrated proof-of-concept with 82% complete response rate and no dose-limiting toxicities in early clinical studies, showing potential to redefine standard-of-care for mutCALR-driven essential thrombocythemia with upside potential in myelofibrosis.[1]
- Therapeutic areas
- Hematology
- Modalities
- Monoclonal antibodyBispecific monoclonal antibody
- Industry
- Biotech
02
Drug pipeline
7 assets6 more assets in the full pipeline.
Request access →03
Financials
- Market cap
- $1.8B
- Total revenue
- $0
- Enterprise value
- $1.3B
Beyond the preview
Go deeper on Damora Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Damora Therapeutics.